Lantern Pharma (LTRN)
Develops oncology candidates using data science and biomarker-guided drug development.
$1.93
Pre-market0.00 (0.00%)
At close$1.93(−4.46%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions33 holders · as of Mar 31, 2026 | 16.40% | 2.10M shares | |
| Insiders6 holders · as of May 14, 2026 | 22.73% | 2.91M shares | |
| Otherremainder | 60.87% | 7.78M shares |
12.78M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
33 holders · 2.10M shares · 5 new positions · 14 increased · 9 reduced · 6 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Bios Capital Management, LP | 864.4K | 6.76% | −145.1K | May 13, 2026 |
| Vanguard Capital Management LLC | 332.1K | 2.60% | +332.1Knew | May 15, 2026 |
| CM Management, LLC | 250.0K | 1.96% | +25.0K | May 8, 2026 |
| Renaissance Technologies LLC | 116.0K | 0.91% | +5.6K | May 14, 2026 |
| Geode Capital Management, LLC | 111.6K | 0.87% | +14.9K | May 15, 2026 |
| Westside Investment Management, Inc. | 50.1K | 0.39% | +14.2K | May 4, 2026 |
| Voss Capital, LLC | 50.0K | 0.39% | 0 | May 15, 2026 |
| Vanguard Fiduciary Trust Co | 49.6K | 0.39% | +49.6Knew | May 8, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Empery Asset Management, LP | 9.99% | 1.32M | 13G | Aug 4, 2026 ↗ |
| Thomas A. Satterfield, Jr. | 5.10% | 570.0K | 13G | Apr 3, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| May 12, 2026 | D. Jeffrey Keyserdirector | Purchase · 2 lots | 97,088 | $2.17 | 142,847 |
| May 12, 2026 | Lee Troy Schalopdirector | Purchase · 2 lots | 97,088 | $2.17 | 97,088 |
CongressHouse and Senate disclosures
Not reported.